Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $27
Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $14 to $27.
Last updated: 2026-11-19 02:37:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Replimune Group, Inc. (REPL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $19.80, with a market capitalization of $2.03B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.50 to $23.54. This page covers its latest market performance, valuation, price trends and company information.
$2.03B | |
$19.63 | |
$20.13 | |
$19.35 | |
$19.69 | |
1.77M | |
2.54M | |
-- | |
$23.54 | |
$1.50 | |
-- | |
2026-09-30 |
Replimune Group, Inc. (REPL) last closed at $19.80 as of 2026-11-19 00:46:00, up 0.56% ($0.11) from the previous close of $19.69.
During the latest regular trading session, REPL traded between $19.35 and $20.13, with a volume of 1.77M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Replimune Group, Inc. (REPL) moved from $22.26 to $19.80, representing a decline of 11.04% ($2.46).
The stock traded between $19.35 and $23.54 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.66 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 83.0%
REPL is currently trading at $19.80, placing it 83.0% of the way from its 52-week low of $1.50 to its 52-week high of $23.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 465 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Replimune Group, Inc. and REPL stock.
Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $14 to $27.
Replimune's stock surged 80% over the past month following FDA accelerated approval and commercial launch of Tudriqev (RP1) in combination with Bristol Myers' Opdivo for treating unresectable advanced cutaneous melanoma. Early adoption at leading melanoma centers and better-than-expected Q2 2027 earnings results drove investor confidence. The company's pipeline candidate RP2 is advancing in multiple cancer indications with preliminary results expected in Q1 2027.
Eligible investors can buy real shares of Replimune Group, Inc. (REPL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to REPL, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between REPL shares and USD.
REPL Shares to USD
1.00 REPL shares = 19.803 USD
Calculations are estimates based on the latest available price and are for reference only.